Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

Contributing writer

Rebecca Nguyen, MB, BS, FACD
Skin and Cancer Foundation, Monash Health and Eastern Health
Melbourne, Australia

Rebecca Nguyen is a consultant dermatologist at the Skin and Cancer Foundation, Monash Health and Eastern Health, Melbourne, Australia. She completed her dermatology training in 2016 and has published as lead author on 8 peer-reviewed manuscripts. Dr. Nguyen is a 2019 IPC International Fellow and as part of her yearlong fellowship will work with IPC Professor Carle Paul in the dermatology department of Paul Sabatier University in Toulouse, France.

Last Updated: Aug 13, 2019

  

Psoriasis News

8/20/2019 10:08:00 AM
Eli Lilly and Company (NYSE: LLY) announced that Taltz® (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R study, which evaluated the efficacy and safety of Taltz versus TREMFYA® (guselkumab) in people living with moderate to severe plaque psoriasis (PsO).
8/6/2019 11:36:00 AM
Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
8/1/2019 7:19:00 AM
On 25 May 2019, the World Health Assembly officially adopted the eleventh revision of the International Classification of Diseases (ICD-11). The ICD-11 will come into effect on 1 January 2022.
8/1/2019 7:09:00 AM
Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA® (adalimumab)i , for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, and plaque psoriasis. Please see full indications and Boxed Warning for HADLIMA™, below.
More News

This website uses cookies. Please ensure your cookies are enabled. 
OK